Efficacy and influencing factors of iodine-125 seed implantation on the treatment of recurrent radioiodine refractory differentiated thyroid carcinoma
10.3760/cma.j.cn115807-20250308-00063
- VernacularTitle:碘-125粒子植入治疗复发碘难治性分化型甲状腺癌的疗效及影响因素
- Author:
Shule REN
1
;
Zhen GAO
;
Hongtao ZHANG
;
Huimin YU
;
Zezhou LIU
;
Shanshan SHEN
Author Information
1. 河北省人民医院肿瘤一科，石家庄 050051
- Publication Type:Journal Article
- Keywords:
Dose;
Thyroid carcinoma;
Iodine-125 seed;
Therapeutic effect
- From:
Chinese Journal of Endocrine Surgery
2025;19(4):541-546
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the efficacy and influencing factors of iodine-125 seed implantation in the treatment of recurrent radioiodine refractory differentiated thyroid carcinoma (RAIR-DTC) .Methods:Retrospective analysis of 18 patients with recurrent RAIR-DTC treated with iodine-125 particle implantation at Ward One, Department of Oncology, Hebei General Hospital from Sept. 2015 to Mar. 2022 was performed. A total of 35 lesions were involved, all permanently implanted with iodine-125 particles under image guidance, with particle activity ranging from 0.3mCi to 0.8mCi, and prescription doses ranging from 80 to 140 Gy. The study observed the objective response rate, local control rate, survival rate, adverse reactions, and factors influencing treatment efficacy.Results:After a follow-up period of 8 to 115 months,according to the objective efficacy evaluation criteria of solid tumors 1.1,the objective response rates were 51.4% (18/35) ,80.0% (28/35) ,68.6% (24/35) ,60.0% (21/35) ,42.9% (15/35) at 3,6,12,24,36 months postoperatively,respectively.The local control rates were 100% (35/35) ,100% (35/35) ,80.0% (28/35) ,62.9% (22/35) ,51.4% (18/35) at 3,6,12,24,36 months postoperatively,respectively.The 1-,2-, and 3-year postoperative survival rates were 83.3% (15/18) ,72.2% (13/18) ,61.1% (11/18) ,respectively.During the follow-up period,4 patients developed progressive lesions in the target area.One grade I radioactive skin injury,one grade Ⅱ radioactive skin injury,and no residual particle-related adverse reactions.The results of multivariate analysis showed that D90,tumor involvement of the esophagus were the factors influencing the recent efficacy.The area under the ROC curve for D90 was 0.804 with the best bound of 106.5Gy.Conclusion:Iodine-125 particle implantation is safe and effective for recurrent RAIR-DTC.D90,tumor involvement of the esophagus are the influencing factors of the recent efficacy,and the D90≥106.5Gy treatment effect is better.
